RaQualia, CJ Group in gastrointestinal deal

RaQualia Pharma Inc. (JASDAQ:4579) granted CJ Group (Seoul, South Korea) exclusive rights to develop, manufacture and commercialize RaQualia's gastrointestinal candidate RQ-00000010 in Korea, China, Taiwan, India and Southeast Asia. RaQualia will receive an upfront payment and is eligible for development milestones and royalties. The serotonin (5-HT4) receptor partial agonist is in preclinical development to treat functional dyspepsia and other gastrointestinal motility disorders, including chronic constipation. Terms were not disclosed. ...